text:
bringing health insight
Treat the
Untreatable
Our pipeline of first-in-class oral therapies, which is built on our RBP4 (Retinol Binding Protein 4) platform technology, is focused on meeting the unmet needs of patients suffering from blindness, liver disease and diabetes.
First-in-Class Treatment for
Unmet Medical Need
Belite Bio™ is a San Diego-based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes.
Developed from our RBP4 platform technology, our lead candidate, LBS-008, is currently in a Phase I clinical trial for dry age-related macular degeneration and its juvenile form, Stargardt disease. LBS-008 has received Orphan Drug Designation in the US and Europe, as well as Rare Pediatric Disease Designation in the US.
TURN HOPE INTO HEALTH
We are a drug development company targeting untreatable age-related diseases.
Belite Bio™ is clinical stage biopharmaceutical drug development company developing anti-RBP4 therapies to treat age-related metabolic diseases, including macular degeneration, liver disease and diabetes.
Dr Tom Lin
MBA MMed PhD (Med)
Dr. Tom Lin graduated from The University of Sydney Medical School with a multi-disciplinary specialization in cardiology, neurology, and immunology, and was awarded a PhD in Medicine for his research and development of immunotherapies in the treatment of autoimmune neuropathies. During his doctoral training, Dr. Lin was also awarded a fellowship at The University of Melbourne, where he completed his Specialist Certificate in Clinical Neuroscience, and trained under visiting professor, Dr. Barry Marshall (Nobel Laureate in Medicine) in clinical research and drug development.
Dr. Lin's educational background also includes participation in the Clinical Scholars Program from Harvard Medical School and The Royal college of Physicians (London), and an Executive MBA and Global Chief Executive Program from Columbia University, London Business School, and Wharton Business School. Prior to founding Lin BioScience, Dr. Lin has served as President, Chief Operations Officer, and Medical Director for biotech and pharmaceutical companies. Dr. Lin has a vast clinical and drug development experience in cardiovascular, oncology, immuno-oncology, autoimmune and anti-inflammatory therapeutic areas, and has a successful track record in taking biotech start-up companies to IPO.
Dr Irene Wang
PhD MBA
Dr. Wang founded Belite Bio™ in Dr. Tom Lin's team in 2016 as R&D Director and President of Belite Bio™ 's US subsidiary. She is experienced in drug discovery specifically in preclinical and early clinical development. Over her career, Dr. Wang has led discovery programs that advanced investigational medicines into clinical development in different therapeutic areas, including oncology and ophthalmology drug development. Dr. Wang received a Bachelor of Science in Chemistry, a PhD in Biological Sciences from National Taiwan University, and her MBA degree from University of California, San Diego. She was a postdoctoral fellow at The Scripps Research Institute (TSRI).
Prior to joining Belite Bio™ , Dr. Wang served as Director of Research & Development for biotechnology start-ups. Dr. Wang has demonstrated her leadership in CMC, preclinical & pharma/tox, companion diagnostics, clinical & bioassays and global phase 2 clinical development, and regulatory submissions.
Hao-Yuan Chuang
CFA MBA FRM
Mr. Chuang is a Charted Financial Analyst and a certified Financial Risk Manager. He graduated from The National Taiwan University with a Bachelors in Economics, and a joint Global Executive MBA from The University of Hong Kong, London Business School, and Columbia University.
Prior to joining Belite Bio™ , Mr. Chuang served in several executive and director positions for leading Chinese multinational corporations and Hong Kong listed companies. During that time Mr. Chuang led several high-profile IPOs, investments and acquisitions. These include Vanke's Hong Kong reverse takeover, the acquisition of Inter Milan (Italian Series A-League Football Club) for Suning Group, outbound direct investments for The People's Insurance Company of China Asset Management, multi-billion-dollar multinational properties acquisitions and IPO for Wanda Group, and Agricultural Bank of China's IPO (world's second largest IPO) at CITIC Securities International.
LBS 008
Bringing Hope to
Incurable Blindness
Dry AMD / Stargardt Disease
hope to incurable blindness
For Dry Age-Related Macular Degeneration
LBS-008 is a first-in-class oral therapy targeting Dry Age-Related Macular Degeneration (AMD) and Stargardt Disease, which are untreatable conditions that cause vision loss in adults and children, respectively.
LBS-008 is an RBP4 inhibitor that prevents the buildup of toxins in the eye that cause Dry AMD and Stargardt. The toxins are a byproduct of the eye's visual cycle, which is dependent on the presence of vitamin A (retinol). LBS-008 works by reducing the amount of circulating vitamin A, and consequently reducing vitamin A uptake into the eye, thus preventing the formation of the toxins associated with macular degeneration.
LBS-008 is the most advanced and the first graduate candidate from the US National Institutes of Health's (NIH) highly selective Blueprint Program for Neuroscience Research. The program leveraged the resources of 15 NIH centers and $10M USD in funding to cover the development cost of LBS-008 through completion of Phase 1 clinical trials. LBS-008 has entered first-in-human phase 1 study in Australia in October 2018 and is expected to complete this study during the 2nd half of 2019. LBS-008 has obtained Orphan Drug Designation in the United States and Europe, as well as being awarded Rare Pediatric Disease (RPD) status in the US.
Disease Profile
Dry AMD
Age-related Macular Degeneration (AMD) is a disease that can cause irreversible loss of our central vision, which we use for seeing fine details during activities like reading, driving and recognizing faces. It is the leading cause of blindness in people over the age of 50 globally. While there are two forms of the disease, 90% of cases of severe vision loss are caused by dry AMD. Because no treatment currently exists, dry AMD is devastating for patients, affecting 170M people worldwide (11M in the US alone).
Stargardt disease is the inherited juvenile form of macular degeneration, which affects 1 in 8,000-10,000 children. Patients suffer from progressive vision loss starting in childhood, with most patients becoming visually impaired by the age of 20. The disease is caused by a mutation in the ABCA4 gene, which leads to the accelerated formation and accumulation of toxic vitamin A dimers in the retina that cause progressive retinal cell death and permanent loss of vision. Currently, there is no treatment for Stargardt disease, which is an orphan indication.
Preventing the Toxic Accumulation of Lipofuscin
In order to see, light rays must pass through the eye and hit the light sensitive area at the back of the eye called the retina. Dry AMD and Stargardt occur when the center of the retina, known as the macula, is damaged. The macula is made up of several layers of cells that work together to allow us to see clearly. The inside layer of the macula is made of photoreceptors (rods and cones) that react to light and send signals to the brain. Immediately behind the photoreceptors is a supportive layer of retinal pigment epithelium (RPE) cells. In addition to providing photoreceptors with structural support, RPE cells also supply them with nutrients and remove waste. It is believed that AMD is caused by the abnormal buildup of a yellow pigment, called lipofuscin, below RPE cells. As lipofuscin accumulates, it disrupts the rod and cone cells, causing them to die. Vision loss progresses with the death of photoreceptors. By modulating the amount of retinol entering the visual cycle, LBS-008 reduces the formation of lipofuscin associated with macular degeneration and maintains the health of retinal tissues.
Visual Cycle
During the visual cycle, light is converted into electrical signals and sent to the brain for visual processing. This cycle of vision depends on the presence of vitamin A, which is transported from the blood into the RPE by circulating retinol binding protein (RBP4). Once inside the RPE, retinol goes through several isomerizations until it reaches the photoreceptors as 11c-Ral. When light hits the photoreceptors, 11c-Ral is isomerized to at-Ral, which initiates the visual cycle. A natural and cytotoxic byproduct of this process is a substance called A2E, which contributes to lipofuscin accumulation in AMD and Stargardt. RBP4 is the primary bloodstream transporter of the precursor of A2E, at-Rol, to the RPE.
Blocking the Path to
Non-Fatty Liver Disease / Type 2 Diabetes
Preclinical
the path to metabolic disease
For Non-Alcoholic Fatty Liver Disease & Type 2 Diabetes
LBS-009 is a first-in-class anti-RBP4 oral therapy targeting liver disease and type 2 diabetes, two age-related metabolic diseases. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and type 2 diabetes cumulatively impact more than 1.89 billion patients worldwide. Many studies in the peer-reviewed literature have focused on the role of RBP4 in both diseases, confirming that elevated levels of RBP4 are a contributing factor. The combined projected global market for NAFLD/NASH and diabetes is $79 billion dollars.
LBS-009 is currently in preclinical development, and is expected to enter first-in-human Phase 1 clinical trials in 2020.
Non-alcoholic fatty liver disease (NAFLD) occurs when an excess accumulation of fat damages the liver. Currently, it's estimated that 1.46 billion patients suffer from NAFLD worldwide.
Over time, the liver damage and the associated inflammation can lead to the development of non-alcoholic steatohepatitis (NASH), which impacts more than 9 million patients in the United States alone. As the disease progresses, it can lead to cirrhosis and eventually, complete liver failure.
Currently, there are no approved treatments for NAFLD / NASH, and patients often have no symptoms in the early stages.
Type 2 diabetes (T2D) is a chronic disease that occurs when the body cannot effectively use insulin, the hormone that regulates blood sugar levels. The health impact of T2D is profound, potentially causing damage to the heart, blood vessels, eyes, kidneys, and nerves (Source: WHO). Type 2 diabetes is on the rise, with approximately 422 million patients globally (Source: WHO).
RBP4 is a Pro-Inflammatory Metabolic Cytokine
RBP4 has been identified as a pro-inflammatory cytokine in preclinical models of insulin resistance and liver disease and is currently being investigated as a clinical biomarker for human metabolic diseases. In response to the impaired glucose uptake associated with obesity, fat cells will increase their production and release of RBP4. Elevated concentrations of RBP4 in adipose tissue have been shown to activate antigen presenting cells (APC), resulting in an influx of immune cells.
This polarization and proliferation of CD4 T cells further amplifies inflammation, primarily in visceral adipose tissue, and is currently thought to be the driving force in RBP4-mediated insulin resistance. Increased RBP4 production in enlarged adipocytes also instigates a cascade of responses that result in a redistribution of free fatty acids from adipose tissue to the liver, leading to excessive accumulation of hepatic fat. While the role of RBP4 in inducing metabolic dysregulation is both complex and multifaceted, we believe modulating RBP4 concentrations systemically with LBS-009 has significant therapeutic potential for treating patients suffering from metabolically associated diseases.
Anti-RBP4 Platform
Our technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease and diabetes.
Lin BioScience, the parent company of Belite Bio raises $30 million in its rights issue to support LBS-008's phase 3 clinical trial to treat Stargardt Disease
Belite Bio
contact@belitebio.com
Lin BioScience (Taipei Exchange Ticker: 6696), the parent company of Belite Bio, today announced that it has successfully completed its $30 million Rights Issue. The Rights Issue was completed earlier than the scheduled date due to strong oversubscription, with numbers of new institutional investors from Taiwan and overseas participated. The new funding will enable Lin BioScience to continue to invest in Belite Bio to pursue the Phase 3 clinical trial of its lead RBP4 antagonist LBS-008 for Stargardt disease.
LBS-008 and Its Development Status
Belite Bio's lead candidate, LBS-008 is a first-in-class oral small molecule RBP4 specific antagonist aimed to treat atrophic Age-related Macular Degeneration (commonly known as dry AMD) and Stargardt disease, an inherited juvenile form of macular degeneration. LBS-008 has completed its Phase I clinical trials in health volunteers and the data has demonstrated LBS-008's superiority in safety and RBP4 lowering capability. LBS-008 is expected to enter global Phase 3 clinical trial in 2021.
LBS-008 Regulatory Achievements
LBS-008 has received the US and EU orphan drug designation (ODD) in 2017 and 2018, and rare pediatric disease designation (RPD) from the FDA in 2018 for the treatment of Stargardt disease.
LBS-008 Mechanism of Action
LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins in the eye that cause Stargardt disease and contribute to dry AMD. The toxins are by-products of the eye's visual cycle which are produced from vitamin A. LBS-008 works by reducing and modulating a carrier protein, Retinol-Binding Protein 4 (RBP4), that is to transport vitamin A to the eye. LBS-008 does not directly interfere with the visual cycle, and therefore is unlikely to affect the visual cycle rate.
Apr 24 / 2019
Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease
Belite Bio, a drug development company targeting currently untreatable conditions in ophthalmology and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for LBS-008 (BPN-14967), a first-in-class oral therapy for the treatment of atrophic Age-related Macular Degeneration (commonly known as dry AMD) and Stargardt disease, an inherited juvenile form of macular degeneration. LBS-008 will be one of the first drugs to graduate from the US National Institute of Health's (NIH) Blueprint Neurotherapeutics Network (Blueprint Program), which has funded LBS-008's discovery and development, and will continue to provide support and funding until the completion of its Phase 1 single ascending dose (SAD) clinical trial.
"Initiation of the Phase 1 trial is an important milestone for LBS-008, which was funded by the NIH Blueprint Program starting from lead optimization to a preclinical proof of concept." said Dr. Konstantin Petrukhin, Professor of Ophthalmic Science at Columbia University Medical Center, and inventor of the technology. "The combined strength of the academic research conducted at Columbia University and the drug development expertise, resources, and funding provided by the NIH Blueprint Program has enabled LBS-008 to bring hope to millions of patients suffering from untreatable forms of macular degeneration."
"We are excited to announce the start of this Phase 1 trial in the US together with the NIH," said Dr. Tom Lin, Chairman of Belite Bio. "We're encouraged by the ongoing favorable regulatory view of our technology, including a recent systematic review published by the UK National Institute for Health Research identifying the reduction of serum RBP4 as the most promising treatments for dry AMD and Stargardt disease. We plan to continue to work closely with our collaborators and leverage the Blueprint Program's resources and support to move LBS-008 to the next clinical and regulatory milestone."
About LBS-008
LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins (A2E) in the eye that cause Stargardt disease and contribute to atrophic Age-related Macular Degeneration (dry AMD). The toxins are by-products of the eye's visual cycle which are produced from vitamin A. LBS-008 works by reducing and modulating a carrier protein, Retinol-Binding Protein 4 (RBP4), that is to transport vitamin A to the eye. LBS-008 does not directly interfere with the visual cycle, and therefore is unlikely to affect the visual cycle rate.
Belite Bio holds the worldwide exclusive rights for LBS-008. LBS-008 received US and EU orphan drug designation (ODD) in 2017 and 2018, and rare pediatric disease designation (RPD) from the FDA in 2018 for the treatment of Stargardt disease.
Dry Age-related Macular Degeneration
Atrophic age-related macular degeneration (dry AMD) is the main cause of vision loss in the United States, and has zero approved treatments available. There are an estimated 11 million dry AMD patients in the US and over 170 million patients worldwide1 with a global direct healthcare cost of 255 billion US dollars2
Stargardt disease is an inherited juvenile form of macular degeneration, which affects 1 in 8,000-10,000 children3. Patients suffer from progressive vision loss starting in childhood, with most patients becoming visually impaired by the age of 20. The disease is caused by a mutation in the ABCA4 gene, which leads to the accelerated formation and accumulation of toxins from excess vitamin A by-products in the retina that cause progressive retinal cell death and permanent loss of vision. Currently, there is no treatment for Stargardt disease, which is an orphan indication.
About Belite Bio
Belite Bio, a subsidiary of Lin BioScience, is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable diseases, including age-related macular degeneration, Stargardt disease, and liver diseases. For more information, please visit www.belitebio.com.
1. Katie L. Pennington and Margaret M. DeAngelis (2016). Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178091/ (accessed 17 April 2019)
2. BrightFocus Foundation. Sources for Macular Degeneration: Facts & Figures. URL: https://www.brightfocus.org/sources-macular-degeneration-facts-figures (accessed 17 April 2019)
3. Facts About Stargardt Disease, National Eye Institute. URL: https://nei.nih.gov/health/stargardt/star_facts (accessed 14 September 2018)
LBS-008 Recognized in UK NIHR's Systematic Review of Treatments for Dry AMD and Stargardt Disease
Belite Bio (Lin BioScience's subsidiary), a clinical stage drug development company targeting untreatable conditions in ophthalmology and metabolic diseases, announced today that the UK National Institute for Health Research (NIHR) acknowledges LBS-008's potential in treating dry age-related macular degeneration (dry AMD) and Stargardt Disease (STGD). NIHR has conducted a systematic review of 7,948 articles on treatments for dry AMD and STGD and recently published their findings. The report recommended further studies with fenretinide in both dry AMD and STGD as they consider it a treatment with a promising mechanism of action. The NIHR also acknowledges LBS-008 as a treatment with the same mechanism of action, reducing RBP4 to prevent the accumulation of A2E and lipofuscin.
"Following the inclusion of LBS-008 in the US NIH's "Translational Research Success Stories", LBS-008 and it's mechanism of action have received significant attention from NIHR, the top healthcare authority in the UK. "This is very encouraging for our ongoing clinical trials." stated Dr. Tom Lin, CEO of Belite Bio. "We look forward to receiving our interim Phase I clinical trial results mid 2019."
LBS-008 is a first-in-class drug with an RBP4 inhibiting mechanism. Despite this, clinical proof-of-concept has been established in fenretinide's Phase 2b study in dry AMD. In this study, fenretinide treatment produced a dose-dependent reduction in serum RBP4 that was associated with reduced lesion growth rates in dry AMD patients with geographic atrophy when those patients achieved serum RBP4 levels below 1 uM. As fenretinide has a relatively poor ability to lower RBP4, only a subset of patients achieved this level of RBP4 at the highest fenretinide dose.
LBS-008 is expected to have superior RBP4 lowering compared to fenretinide and to achieve RBP4 lowering below 1 uM in a majority of patients. Belite Bio's ongoing Phase 1 study will ensure selection of an optimal dose of LBS-008 that reduces RBP4 to below the target concentration in all or most patients.
LBS-008 targets and reduces RBP4 (the primary carrier of vitamin A) levels in circulation through convenient oral dosing. LBS-008 dose not target or interrupt the visual cycle, instead, it reduces the load of vitamin A (a precursor to the toxic bisretinoid A2E) entering the visual cycle but not the rate of the visual cycle. This will minimize side-effects from direct inhibition of the visual cycle.
Belite Bio (Lin BioScience's subsidiary) is a clinical stage drug development company targeting untreatable diseases. Our therapeutic pipeline, which includes a novel RBP4 platform technology and two first-in-class candidates, is focused on meeting the unmet needs of patients suffering from macular degeneration, liver disease and diabetes.
Oct 2 / 2018
Belite Bio Initiates Phase 1 Study of LBS-008 in Australia
Belite Bio, a clinical-stage biotech company focused on developing first-in-class small molecule antagonists of Retinol Binding Protein 4 (RBP4), announced the initiation of a single-ascending dose phase 1 study of LBS-008 on October 3, 2018. LBS-008, an oral first-in-class small molecule RBP4 specific antagonist, is a potential treatment for atrophic Age-related Macular Degeneration (commonly known as dry AMD) and Stargardt disease, an inherited juvenile form of macular degeneration. The first-in-human phase 1 study is being conducted in healthy volunteers in Australia and is expected to be completed during the 2nd half of 2019.
LBS-008 Phase 1 Trial in Healthy Volunteers in Australia
The LBS-008 phase 1 study is a double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult volunteers. Approximately 72 subjects in total are expected to be enrolled. The primary endpoint for the trial is to evaluate safety, tolerability and pharmacokinetics (PK) of LBS-008. The secondary endpoint is to assess the effects of LBS-008 on plasma levels of RBP4, the pharmacodynamics (PD) marker and potential biomarker that is proposed to correlate to clinical benefit for dry AMD. (ANZCTR registration number: ACTRN12618001823268)
Atrophic age-related macular degeneration (dry AMD) is the main cause of vision loss in the United States, and has zero approved treatments available. There are an estimated 11 million dry AMD patients in the US and over 170 million1 patients worldwide with a global direct healthcare cost of 255 billion US dollars2.
Katie L. Pennington and Margaret M. DeAngelis (2016). Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178091/ (accessed 17 April 2019)
BrightFocus Foundation. Sources for Macular Degeneration: Facts & Figures. URL: https://www.brightfocus.org/sources-macular-degeneration-facts-figures (accessed 17 April 2019)
Facts About Stargardt Disease, National Eye Institute. URL: https://nei.nih.gov/health/stargardt/star_facts (accessed 14 September 2018)
FDA Grants Lin BioScience (Now Belite Bio™) Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease
Lin BioScience (now Belite Bio™), a drug development company targeting untreatable conditions in oncology, ophthalmology and metabolic diseases, announced today that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease.
The Priority Review Voucher Program is intended to encourage development of therapies to prevent and treat rare pediatric diseases. If LBS-008 is approved by the FDA for Stargardt Disease, the RPD designation qualifies Lin BioScience for the Priority Review Voucher. The voucher, which can be sold or transferred to another entity, can be used by the sponsor to receive Priority Review for a future NDA or BLA submission and reduce the candidate's FDA review time to six months.
"We continue to be encouraged by the regulatory support for LBS-008 and the opportunities provided by the Rare Pediatric Disease designation and the Priority Review Voucher Program", stated Dr. Tom Lin, CEO of Lin BioScience (now Belite Bio).
LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins in the eye that cause Stargardt Disease and atrophic Age-related Macular Degeneration (dry AMD). The NIH's Blueprint Neurotherapeutics Network, which funded the therapy's discovery and development, provides support and funding through to the completion of Phase I clinical trials. LBS-008 received both US and EU orphan drug designation in 2017 and 2018, respectively.
About Stargardt Disease
Stargardt Disease is an untreatable inherited condition that causes permanent vision loss in children during childhood and adolescence. This rare disease is caused by a mutation in the ABCA4 gene, which leads to the accelerated formation and accumulation of toxic vitamin A dimers in the retina that cause progressive retinal cell death and permanent loss of vision.
About Lin BioScience, Inc (Now Belite Bio, Inc)
Lin BioScience, Inc. (now Belite Bio, Inc.) is a drug development company targeting untreatable diseases. Our therapeutic pipeline, which includes two candidates with Orphan Drug Status, is focused on meeting the unmet needs of patients suffering from cancer, macular degeneration, liver disease and diabetes.
Lin BioScience (Now Belite Bio™) to Present Highlights for Phase I Clinical Candidates for the Treatment of Macular Degeneration and Cancer at the Biotech Showcase™ Annual Conference on January 10, 2018
Lin BioScience (now Belite Bio™ ), a drug development company specializing in innovative therapies for oncology, ophthalmology and metabolic diseases, announced today that it will be presenting at Biotech Showcase ™ 2018, which will be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
Dr. Irene Wang, President and R&D Director will present at the Biotech Showcase™ as follows:
Date: Wednesday, January 10, 2018Time: 11:15am (PST)Room: Hilton/Franciscan DVenue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA US
Lin BioScience's (now Belite Bio™ 's) lead candidates, which include a first-in-class oral therapy
for macular degeneration (LBS-008) and a natural cell cycle inhibitor for a variety of cancers (LBS-007), are initiating their fully-funded Phase I clinical trials this year. The Company's most recent regulatory milestones was receiving Orphan Drug Status for LBS-008, which is also part of the NIH Blueprint Program.
"We believe our partnership with the NIH Blueprint Program and the Orphan Drug Status designation by the FDA confirms that our approach to developing drug candidates through our RBP4 and oncology platforms show considerable therapeutic promise," commented Dr. Tom Lin, CEO of Lin Bioscience. "We're excited to share the latest developments in our clinical program with potential partners and investors at Biotech Showcase ™ 2018."
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: "We are delighted that Lin BioScience will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018."
About Lin BioScience
Lin BioScience (now Belite Bio™ ) is a drug development company specializing in innovative therapies for diseases with unmet medical needs. Lin BioScience's diverse pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in ophthalmology, oncology and metabolic diseases.
Jan 5 / 2017
Lin Bioscience (Now Belite Bio™) Licenses First-in-Class Therapeutic Program to treat Dry Aged-Related Macular Degeneration from Columbia University in Collaboration with NIH
Lin Bioscience (now Belite Bio™ ) and Columbia Technology Ventures announced today that Lin Bioscience (now Belite Bio™ ) has licensed the intellectual property portfolio and development program for a promising first-in-class medication intended to slow or halt the progression of atrophic "Dry" Age-Related Macular Degeneration (AMD).
Under the terms of this globally exclusive licensing agreement and collaboration model, the National Institute of Health's Blueprint Neurotherapeutics Network, which has funded the medication's discovery and development, will continue to provide financial support through Phase 1, and will continue to collaborate with Columbia University and Lin Bioscience.
AMD is a common degenerative eye condition that can severely impair visual function and eventually, many patients lose the ability to read, handle day-to-day tasks, or even recognize the faces of their loved ones. AMD is the leading cause of blindness in people over the age of 50 and currently, there is no FDA-approved treatment for atrophic "dry" AMD, which accounts for 90 percent of all people with AMD.
LBS-008 is an oral therapeutic candidate that works by reducing retinol in circulation and excess retinal uptake, leading to the formation of toxic byproducts that build up under the retina that causes dry AMD, and similarly in Stargardt Macular Dystrophy, the juvenile onset form of macular degeneration, which is an inherited retinal disease that leads to severe early vision loss in children. LBS-008 is expected to enter Phase 1 clinical trials in 2017 for dry AMD, as well as for Stargardt Disease as an orphan indication.
"Both dry AMD and Stargardt Disease are diseases of real unmet medical need. Globally, dry AMD is a major health concern that severely affects and disabling millions of middle aged to elderly people every day. Up until now, there are no proven treatments, but we are confident that LBS-008, given its potential, may offer some light to the treatment of both diseases," said Dr. Tom Lin, CEO of Lin BioScience (now Belite Bio™ ).
About Lin Bioscience (now Belite Bio™ )
Lin Bioscience is a new drug development company that specializes in the development of innovative drug treatments for diseases with unmet medical needs. Lin Bioscience's diverse and novel pipeline consist of first-in-class drugs aimed to treat life-threatening or disabling diseases in Oncology, Ophthalmology, and Cardiovascular indications.
First Name Last Name Year of Birth Sex Please select Female Male Country of Residence Email Address Phone Number
Condition of Interest Please select Dry AMD Stargardt Comments
I agree with the statement below and with Belite Bio, Inc's privacy policy.
I authorize Belite Bio, Inc ("Belite"), its affiliates and companies working with Belite to contact me by email, telephone, and electronic message for discussing ongoing research, potential eligibility and providing the clinical trial related information.
Please note that there is no guarantee a patient will be enrolled in any clinical trial. Your personal information will be controlled by Belite and stored securely in our electronic filing records and those of the clinic centers. If you wish to remove your personal information from these records at any time, please request removal in writing at clinicaltrial@belitebio.com.
This Privacy Policy applies to Belite Bio, Inc and its affiliates ( "BELITE", "we", "us" and "our"), which are the controllers of your personal information.
Our address is: 3210 Merryfield Row San Diego CA, 92121 USA.
We are committed to protecting your personal information and your right to privacy. If you have any questions or concerns about our policy, or our practices with regards to your personal information, please contact us at clinicaltrial@belitebio.com.
In this Privacy Policy, we seek to explain to you in the clearest way possible what information we collect, how we use it and what rights you have in relation to it. We hope you take some time to read through it carefully, as it is important. If there are any terms in this privacy policy that you do not agree with, please do not provide us with your personal information.
We collect personal information that you voluntarily submit to us when expressing an interest in obtaining information about us or our products, registering for our patient registry, or otherwise contacting us.
If you complete our contact form, we will collect your name, email address, company name, phone number and any additional information you choose to provide in the message portion of our contact form. This information is used to contact you and provide you the requested information or respond to your inquiry,
If you register for our patient registry, we will collect your name, country of residence, date of birth, contact telephone number, e-mail address, and condition of interest. We will also request additional personal information which is recognized as being sensitive such as your gender. This information is necessary for us to identify whether you are potentially suitable to be invited to participate in clinical trials as outlined under the heading 'HOW DO WE USE YOUR INFORMATION' below.
We may automatically collect the following information about your use of our website through cookies and other technologies: your domain name; your browser type and operating system; web pages you view; links you click; your IP address; the length of time you visit our website; and the referring URL, or the webpage that led you to our website. We may combine this information with other information that we have collected about you, including, where applicable, your user name, name, and other personal information. Please see the section "Cookies and Other Tracking Mechanisms" below for more information.
2. COOKIES AND OTHER TRACKING MECHANISMS
We and our third party service providers use cookies and other tracking mechanisms to track information about your use of our website. We may combine this information with other personal information we collect from you (and our third party service providers may do so on our behalf).
Cookies are alphanumeric identifiers that we transfer to your computer's hard drive through your web browser for record-keeping purposes. Some cookies allow us to make it easier for you to navigate our website, while others are used to enable a faster log-in process or to allow us to track your activities at our website. There are two types of cookies: session and persistent cookies.
Session Cookies: Session cookies exist only during an online session. They disappear from your computer when you close your browser or turn off your computer. We use session cookies to allow our systems to uniquely identify you during a session or while you are logged into the website. This allows us to process your online transactions and requests and verify your identity, after you have logged in, as you move through our website.
Persistent Cookies: Persistent cookies remain on your computer after you have closed your browser or turned off your computer. We use persistent cookies to track aggregate and statistical information about user activity.
Most web browsers automatically accept cookies, but if you prefer, you can edit your browser options to block them in the future. The Help portion of the toolbar on most browsers will tell you how to prevent your computer from accepting new cookies, how to have the browser notify you when you receive a new cookie, or how to disable cookies altogether. Visitors to our website who disable cookies will not be able to browse certain areas of the website.
Third Party Analytics
We use automated devices and applications, such as Google Analytics, to evaluate usage of our website. We also may use other analytic means to evaluate our Services. We use these tools to help us improve our Services, performance and user experiences. These entities may use cookies and other tracking technologies to perform their services. We do not share your personal information with these third parties.
We use personal information collected via our website for a variety of business purposes ("Business Purposes") described below, including to:
process, evaluate and respond to requests, inquiries and applications.
provide information or any updates of our drug development and/or information about changes to our terms, conditions, and policies.
identify and notify you of clinical trials which may be suitable for you to be invited to participate in.
for other purposes for which we have obtained your consent
Please note that the submission of your personal information via this website does not mean that you will be invited or selected to take part in any clinical trial either now or in the future.
We rely on one or more of the following legal basis for processing of your personal information:
Contract: We or our service providers may process your personal information in order to perform obligations under any contract, agreement or transaction with you.
Consent: We may rely upon your specific consent to use your personal information in a specific purpose. You may withdraw this consent at any time by notifying us as set forth in Section 13, provided that such withdrawal will not affect any use or processing of your personal information prior to receipt of your withdrawal.
Legitimate Interests: We may process your personal information when it is reasonably necessary to achieve our legitimate interest such as the Business Purposes outlined in Section 3 above.
Legal Obligations: We may disclose your personal information where we are legally required to do so in order to comply with applicable law, governmental requests, a judicial proceeding, court order, or legal process, such as in response to a court order or a subpoena (including in response to public authorities to meet national security or law enforcement requirements).
Vital Interests: We may disclose your personal information where we believe it is necessary to investigate, prevent, or take action regarding potential violations of our policies, suspected fraud, situations involving potential threats to the safety of any person and illegal activities, or as evidence in litigation in which we are involved.
More specifically, we may need to process or share your personal information in the following situations:
Vendors, Consultants and Other Third-Party Service Providers. We may share your personal information with third party vendors, service providers, contractors or agents who perform services for us or on our behalf and require access to such information to do that work. When we do, we require those third parties to handle it in accordance with relevant laws.
Unless described in this Policy, we do not share, sell, rent or trade any of your personal information with third parties for their promotional purposes.
Business Transfers. We may share or transfer your personal information in connection with, or during negotiations of, any merger, sale of company assets, financing, or acquisition of all or a portion of our business to another company.
Affiliates. We may share your personal information with our affiliates, in which case we will require those affiliates to honor this Privacy Policy. Affiliates include our parent company and any subsidiaries, joint venture partners or other companies that we control or that are under common control with us.
5. IS YOUR INFORMATION TRANSFERRED INTERNATIONALLY?
Our servers are located in the United States and Taiwan. If you are located outside of the United States or Taiwan and submit your personal information, please be aware that your information may be transferred to, stored, and processed by us in our facilities and by those third parties with whom we may share your personal information (see "WILL YOUR INFORMATION BE SHARED WITH ANYONE?" above), in Taiwan, United States, and other countries.
If you are a resident in the European Economic Area("EEA), then these countries may not have data protection or other laws as comprehensive as the law of your jurisdiction. By submitting your personal information, you explicitly authorize its transfer, store and process outside the EEA.
If you are not in agreement, please do not submit your personal information on the website.
We will however take all necessary measures to protect your personal information in accordance with this privacy policy and applicable law.
We will only keep your personal information for as long as it is necessary for the purposes set out in this privacy policy, unless a longer retention period is required or permitted by law (such as tax, accounting or other legal requirements).
When we have no ongoing legitimate business need to process or legal obligation to retain your personal information, we will either delete or anonymize it. The deletion of records containing personal information is conducted in a secure manner.
We have implemented appropriate technical and organizational security measures designed to protect the security of any personal information we process. However, please also remember that we cannot guarantee that the internet itself is 100% secure. Although we will do our best to protect your personal information, transmission of personal information to and from our website is at your own risk. You should only access our website within a secure environment.
8. DO WE COLLECT INFORMATION FROM MINORS?
We do not knowingly collect personal information from children under 13 years of age ("Child" or "Children"). By ticking the box at the end of "Patient Registry", you represent that you are at least 13 or that you are the parent or guardian of such a minor and consent to provide such minor dependent's personal information. If we become aware that a Child has provided BELITE with personal information without prior parental consent, we will remove all personal information provided by such underage user from our database. If you believe we have collected personal information about your Child without your consent, you may contact us at clinicaltrial@belitebio.com and request that we remove information about your Child.
In some regions (such as the European Economic Area), you have certain rights under applicable data protection laws. These may include the right (i) to request access and obtain a copy of your personal information, (ii) to request rectification or erasure; (iii) to restrict the processing of your personal information; and (iv) if applicable, to data portability. In certain circumstances, you may also have the right to object to the processing of your personal information. To make such a request, please use the contact details provided below. We will consider and act upon any request in accordance with applicable data protection laws.
If we are relying on your consent to process your personal information, you have the right to withdraw your consent at any time. Please note that this will not affect the lawfulness of the processing before its withdrawal. Your withdrawal of consent is not retroactive. This means we will not remove information that has already been disclosed or processed.
If you have any questions or concerns about our Privacy Policy or data processing or if you would like to make a complaint about a possible breach of our Privacy Policy, please contact us using the contact details provided below. You also have the right to complaint to the Ombudsman under the Cayman Island Data Protection Law.
If you are a resident of the European Economic Area, you have the right to submit complaints to the supervisory authority in your jurisdiction of residence.
10. CONTROLS FOR DO-NOT-TRACK FEATURES
Most web browsers and some mobile operating systems and mobile applications include a Do-Not- Track ("DNT") feature or setting you can activate to signal your privacy preference not to have data about your online browsing activities monitored and collected. Many websites and applications, including our website, do not currently respond to web browser DNT signals because such signals are not yet uniform. If a standard for online tracking is adopted that we must follow in the future, we will inform you about that practice in a revised version of this Privacy Policy.
11. DO CALIFORNIA RESIDENTS HAVE SPECIFIC PRIVACY RIGHTS?
California Civil Code Section 1798.83, also known as the "Shine The Light" law, permits our users who are California residents to request and obtain from us, once a year and free of charge, information about categories of personal information (if any) we disclosed to third parties for direct marketing purposes and the names and addresses of all third parties with which we shared personal information in the immediately preceding calendar year. If you are a California resident and would like to make such a request, please submit your request in writing to us using the contact information provided below. Please note that under this law we are not required to respond to your request more than once in a calendar year, nor are we required to respond to any requests that are not sent to the above-designated email address.
If you have questions or comments about this policy, you may contact our Data Protection Officer (DPO), by email at clinicaltrial@belitebio.com or by post to:
Belite Bio, Inc.
3210 Merryfield Row
San Diego CA, 92121 USA
First Name Last Name Email Address Phone Number
Company Name Message
Belite Bio™ Inc @JLABS San Diego


Collect 239 Loyalty Points from this purchase.
Powers John's Lane Release is a single pot still whiskey that celebrates the origin of the Powers Whiskey tradition. The distillate has been matured for no less than 12 years, mainly in American oak casks with a small inclusion of Iberian oak for balance and complexity and then married to create the distinctive honey and spice flavour.
The aroma has plenty of earthy notes, leather, tobacco with layers of charred wood, dark chocolate and treacle toffee. The flavour is full bodied spice front followed by vanilla, honey and dried apricot. The finish has a lingering honey sweetness on toasted oak.


text:
Home Birth Injury in Hospital
Settlement Approved in Claim for Medical Negligence at the Midwestern Regional Maternity Hospital
Birth Injury in Hospital, Delayed Treatment due to Hospital Negligence, Hospital Medical Negligence
A €1.75 million interim settlement of a claim for medical negligence at the Midwestern Regional Maternity Hospital has been approved at the High Court.
The claim for medical negligence at the Midwestern Regional Maternity Hospital in Limerick was brought by two-year-old Charlie Enright, whose mother Catriona was admitted to the hospital on August 19th 2013, thirty-seven weeks pregnant with her son.
After tests were conducted on Catriona, doctors made the decision to induce labour and administered Syntocinon. However, despite the well-chronicled side effects of Syntocinon, there was a failure to adequately monitor Catriona´s condition as Charlie suffered hyper-stimulation in the womb.
Due to the misinterpretation of a cardiotocography trace and the belated recognition of foetal distress, Charlie was born "flat" the following morning – unable to breathe by himself. The new-born child was transferred to Cork University Hospital, where he was diagnosed with an intra-cranial haemorrhage underwent therapeutic hypothermia treatment on his head.
Despite the rapid action to prevent brain damage after his birth, Charlie is permanently disabled due to the lack of care his mother received prior to his delivery. On her son´s behalf, Catriona made a claim for medical negligence at the Midwestern Regional Maternity Hospital against the Health Service Executive (HSE) – who, after an investigation into the claim, admitted liability for Charlie´s birth injuries.
Negotiations started to settle the claim for medical negligence at the Midwestern Regional Maternity Hospital; but, as Charlie´s future needs are not yet determined, a €1.75 million interim settlement of the claim was agreed to cover Charlie´s care and medical expenses for the next two years. To ensure that the interim settlement was appropriate, an approval hearing was scheduled for the High Court.
At the approval hearing, Mr Justice Anthony Barr said that the interim settlement was a very good one. He approved the interim settlement and adjourned the hearing for two years, by which time Charlie´s future needs should have been determined and his mother will have the option of accepting a lump sum or assuring Charlie´s future care through a system of periodic payments.

redpajama_set_name: RedPajamaCommonCrawl


The spa town of Malvern grew fashionable from the 18th century onwards thanks to the fashion for taking mineral waters for their health-giving properties. The town has always been bound to the nearby hills and springs and these attracted fashionable Georgian and Victorian visitors to the Malvern, resulting in a programme of housebuilding and expansion. The newly completed Great Malvern route with its information panels, fun pavement studs and a series of benches with pertinent ends offers a fun way to uncover the town's history, famous visitors and curious features step by step. Cap it off with a visit to St Ann's Well Café and find out more at Malvern Museum in the priory gatehouse.
Most noted for... the Three Counties showground. Purpose-built, it has exhibition halls, arenas and show rings, with parking, offices and general amenities on a 90-acre site. More than a million visitors attend its many and varied events annually. Besides the Three Counties Show held on June 14-16, 2019, look out for the Royal Horticultural Society's Malvern Spring Festival (May 9-12), antiques fairs, transport festivals and animal shows.
While you're here... catch a performance at the Malvern Theatres complex, which offers top-class drama, ballet and live music throughout the year.
But try not to... get lost in a fantasy wonderland. It's said the sight of a single lamp post one snowy night inspired CS Lewis's iconic Narnia chronicles. Around 80 of these lamps remain around the town and a marked trail is available from Malvern Tourist Information Centre.
The Pomp and Circumstance composer Edward Elgar lived most of his life around Malvern, and was buried in Little Malvern cemetery. Charles Dickens's daughter Annie, Victorian soprano and philanthropist Jenny Lind, and thesaurus compiler Peter Mark Roget also have graves in Malvern's cemeteries. Novelist George Bernard of Pygmalian fame, was a regular visitor and instrumental in founding Malvern's drama festival. Author CS Lewis frequented the pub and the hills with his Oxford pal JRR Tolkien. Young Franklin D Roosevelt – later 32nd President of the United States – convalesced locally in 1889. Other notables include songwriter Stephan Duffy, novelist David Mitchell, cricketer Graeme Hick, violinist Nigel Kennedy, and former home secretary Jacqui Smith.
Celebrate composer Edward Elgar's life by cycling around Malvern. An archive of his maps and marked routes, including a photograph of Elgar cycling in the Malverns near his Birchwood Lodge home, has been set at his birthplace in Lower Broadheath. A letter from the time declares there was hardly a Malvern trail he hadn't ridden.
Malvern has inspired a number of acclaimed writers, starting with the 14th century poet William Langland, author of Piers Plowman, whose narrator begins with a vision in the Malvern Hills. During the 1930s, the poet WH Auden taught at The Downs School in the Malvern Hills, and his poem, The Malverns, reflects on their beauty. And JRR Tolkien drew comparisons between the hills and the White Mountains of Gondor in The Lord of the Rings.
Malvern celebrates links with dynamic and creative people and businesses, such as the Morgan Motor Company, and those based at the Wyche Innovation Centre. RADAR was developed at Great Malvern College during World War II, and today Malvern is a centre for cyber security. Find out more at the annual Malvern Festival of Innovation, which runs from October 7-12, 2019.
And get: A split-level architect designed mid-20th century home, with five bedrooms, wrap-round gardens and spectacular Severn Valley views.
Why? This lovely little café and brasserie-restaurant opens from 10am-6.30pm midweek. Its hours are extended on Friday and Saturday nights for fine dining, and on Sundays for brunches.
Why? It's a free house with an excellent range of local ales, guest beers and wines, plus 24 whiskies and 18 different gins ranging from handcrafted botanicals to well-known brands.
Why? This grand ivy-clad four-star hotel has 103 bedrooms and great views across the Vale of Evesham. Built on the site of the Priory House, it is flanked by both Malvern Priory and Malvern museum.


This is such a good, varied list of properly achievable things! I also want to learn to drive this year - like you, I tried at 17 but my instructor made me cry haha. Need to get it sorted! All your trips away, and the big holiday to Nashville next year, sound amazing! I am so looking forward to reading how you get on with them. I went to Munich in August and it was beautiful, and I also love Paris. You'll have a blast!
Good luck with all of these goals - I have a feeling you're going to smash them though!
Thank you lovely! There'll definitely be details of the trips coming up on the blog :) We've been to Munich before but never for Oktoberfest so I'm very excited for that in particular. Good luck with learning to drive too!
Ooh exciting! Good luck with your new tattoo :) How did you find getting your first one?
Sounds like a brilliant list. All of my tattoos are music-related (and my first was a Ryan Adams one, which is ALMOST country music, or at least was then) so I'm really keen to see what you get!
I put learning to drive on my 40 before 40 list, which gives me just over four years to get a move on. I sat my last (10th, I think) driving test on the day before my 30th birthday, and really thought that was going to be it, but it increasingly seems like it's not meant to be. Not saying that to put you off, rather that other older learners inspire me!
Thanks lovely! It's going to be an arrow on the inside of my left foot (a reference to one of my favourite songs, Follow Your Arrow by Kacey Musgraves).


text:
(480) 948 5170 Reserve Now
Click to Tour Our Property
(480) 948 5170 info@elchorro.com
About El Chorro
An Iconic Arizona Destination for Dining, Drinks, and Unforgettable Milestones
Rich tradition, culinary excellence, and unparalleled romance come together at El Chorro to create an experience that is purely Paradise Valley. Cozily nestled between Scottsdale and Phoenix, Paradise Valley's historic El Chorro offers an authentic Arizona dining experience. Generations of Valley residents and visitors have travelled to this serene setting at the base of the stunning Camelback and Mummy mountains. With its breathtaking views and unmatchable Arizona charm, El Chorro is an excellent setting for any occasion — be it a relaxed brunch, romantic dinner, or the wedding of your dreams.
A History of Excellence
This beautiful Arizona escape has a long history of delighting Valley residents, guests, and beloved celebrities. Dining and cocktails on the patio at El Chorro along with its famous Sticky Buns is a long-standing Valley tradition.
El Chorro was originally built as the Judson School for Girls by Dr. John C. Lincoln in 1934 so his daughter Lillian could attend school while he was building Camelback Inn. The schoolhouse and surrounding 22 acres were purchased by Jan and Mark Gruber in 1937 when the girls school combined with the Judson School. The original schoolhouse was converted to a restaurant and lodge. During the winter El Chorro became the "watering hole" (derived from Spanish) for Camelback Inn's guests as the Inn did not offer alcohol. During the 50's, well-known icons like Milton Berle and Clark Gable frequented this Paradise Valley favorite as a hideaway from Hollywood.
Purchased by longtime employees Joe and Evie Miller in 1973, El Chorro's rustic, familiar charm was expanded upon, allowing the Lodge to hold more guests and stay open year-round.
Noted Valley philanthropist and long-time Paradise Valley resident, Jacquie Dorrance acquired El Chorro in 2009 and was joined by operating partners Kristy and Tim Moore. Under this new leadership, El Chorro has maintained a welcoming atmosphere for young and old alike, becoming a comfortable place for memories to be made and rituals to be honored.
Honored with 'Leed' Green Certification
With some of the country's most picturesque views at its doorstep, preservation of natural resources is an integral part of El Chorro's mission.
As part of the renovation of the historic Paradise Valley facilities, El Chorro incorporated a number of green-building features, including a solar-energy water heating system and solar electric panels that reduces the restaurant's energy use by more than 50 percent. It also features eco-friendly insulation made of recycled blue jeans. More than 75 percent of the materials used in the redesign were salvaged from the original restaurant, including 80+ of the original plants.
Because of this dedication to sustainability, El Chorro became the first restaurant in Arizona to earn the U.S. Green Building Council's Leadership in Environmental and Energy Design (LEED) Gold Certification. The designation is the only universally recognized green-building pedigree, with the Gold Certification being the second-highest level attainable.
El Chorro is proud to represent the crossroads at which 21st century ideals meld with beloved heritage. We can't wait for you to enjoy this historic Paradise Valley fine dining experience.
Brunch: Sun: 9:00 am - 2:00 pm
Dinner: Wed-Sun 5:00 pm
Paradise Valley, AZ 85253
info@elchorro.com
© 2021 El Chorro Lodge All Rights Reserved
Site Design & Hosting by LP Creative Co


As avid followers of Mike Fahrion's blog (Technical Product Director at B&B Smartworx) we often share some of his posts here. This one is worth a read as it helps highlight some of the concerns regarding the migration to the Internet of Things…hope you enjoy!
Temporarily escaping another interminable Midwestern winter was a treat by itself, and the 2015 M2M Evolution conference in Miami was icing on the cake. B+B SmartWorx, using our new company name and brand identity, had a large presence as a sponsor and an exhibitor, while also filling three speaking slots. I spent a sizeable portion of my own time delivering a keynote and presenting at tech sessions, describing the ways in which the publish/subscribe MQTT protocol can be leveraged in IoT systems as well as discussing the migration from SCADA to industrial IoT. But I also got to spend a lot of time mixing it up with thought leaders from every aspect of industrial IoT. And I didn't have to wear a parka to do it.
In my conversations with customers, technology partners and industry analysts, I was reminded that many people are still hesitant to take their first step into industrial IoT. They're failing to take advantage of opportunities that already exist. It's not that interest could possibly be any higher, or that they can't see the benefits that IoT information streams can provide. But, for many people, this whole "IoT" thing is still a bit too fuzzy and they're having some trouble getting their arms around it. In most cases they are overthinking it. In their quests to devise the perfect, fully baked "IoT Strategy", and with their concerns about making some costly mistake, they prevent themselves from doing anything at all. Many seem to think that migrating to industrial IoT tech will have to be a single, light switch event that instantly renders all of their existing systems obsolete. That's certainly a scary thought. Thankfully, it's also a load of hooey.
We do need to stop architecting point-in-time solutions to point-in-time problems, andgenerating silo after silo of equipment, personnel and data. But we don't need a crystal ball that can see five years into the future before we can start implementing IoT tech to eliminate the silos. One of the beauties of IoT concepts is the technical flexibility. Industrial IoT will incorporate existing infrastructure, rather than replacing it, and a huge proportion of the "things" included in the "Internet of Things" will be devices that are already out there. The difference is that those devices won't be trapped in their silos anymore. Rather than reporting only to HMIs, PLCs or some single application on the network, they will be able to make their data available to any application, anywhere that the data can be useful.
Granted, it's currently a lot more confusing than it needs to be. New "IoT" software platforms keep popping out of every nook and cranny, and there are already so many that it's hard to keep up. There's lots of money being invested in that arena and I'm sure we'll keep seeing plenty of activity. But there will inevitably be some consolidation. The winners will be the software tools that make it the easiest to distill information from multiple sources while enabling the transition from simple data reporting to predictive, and then prescriptive, analytics.
Full IoT solutions are complex, as they require expertise in both IT technology and operations (OT) technology. But this complexity spells opportunity for many people. That includes many of my blog readers, as well as any solutions company that has specific application expertise, understands OT and has a strong IT background. In most companies the divide between IT and OT is too large. An IT department that has a strong operations background is extremely rare. An Operations side that is equipped to handle IT issues is equally rare. So tomorrow's industry leaders will be the companies that can close the gap between IT and OT before their competitors do.
Industrial IoT isn't a destination; it's a journey. Every company will migrate to industrial IoT at its own pace, deploying appropriate IoT technologies when they see opportunities to cut costs, increase efficiencies and improve processes. Many companies have already begun reaping the rewards that IoT information streams can provide, simply by implementing IoT tech that is already available. They're not uprooting their existing infrastructure. They're simply adding some IoT tech to the mix and acquiring some exciting new capabilities. They may not be where they'll be five or ten years from now, but at least they've picked up the car keys and begun the journey.


The Nature Conservancy of Canada has protected more than 800 hectares of forested land adjacent to New Brunswick's Bartholomew River, an important spawning ground for at-risk Atlantic salmon.
The acquisition represents the largest private-land conservation project in the province's history and creates a continuous corridor of protected land between two tributaries of the Miramichi River, one of the biggest producers of wild Atlantic salmon in North America.
Atlantic salmon numbers have been in steep decline in Canada since the 1990s, with 2014 described as a "crisis year" by the Atlantic Salmon Federation.
"The big concerns with Atlantic salmon tend to be more about international fishing and survival at sea, but within our watersheds in New Brunswick we have significant and healthy salmon runs," said Paula Noel, program director for the NCC in New Brunswick.
"We need to make sure we're doing all we can to protect the integrity and health of the spawning grounds."
The new protected area includes five kilometres of waterfront along the Bartholomew, within which are found two deep cold-water pools — an important rest stop for salmon as they make their way upriver to spawn.
The NCC also identified three at-risk bird species — the eastern wood pewee, common nighthawk and rusty blackbird — nesting on the property, as well as habitat supporting moose, black bears, coyotes, weasels, beavers, snowshoe hares and a variety of amphibians and waterfowl.
"There's so much diversity and so many different habitat types within the area," Noel said. "Our goal for the reserve is to manage it and ensure all the species it supports continue to thrive."
The protected area will be named the Foxner Reserve in honour of the Fox and Faulkner families, who donated the land to the NCC through the Government of Canada's Ecological Gifts Program.


text:
MORE Recordings >>
Nai Palm - Needle Paw (Sony Masterworks)
by Ryan Gabos
Excavating past the funky melodic bass lines, the ever-shifting and expertly syncopated drum beats, and the walls of keyboard so multilayered that it must have taken the many arms of the goddess Durga to produce; in the jazz-coated center of Melbourne's inimitable hip-hop quartet Hiatus Kaiyote lies Nai Palm. She is their rock, as they say in marriage, and it's clear venturing back to old YouTube videos of Palm performing solo – particularly this one, where she performs "Mobius Streak" solo in a loft along with some sort of exotic bird that nabbed a seat in the coveted right shoulder balcony – that the majority of the work they've crafted together all circles back to the starting blocks of her voice and guitar. "Starting blocks" almost reads as a disservice to the music once you've heard it: her vocals combine such bold expression with a smoky perfect pitch that one doesn't even consider the onslaught of jazz-infused guitar stylings underneath it all.
Palm's songwriting never settles for anything less than impressive. Each hook, transition, and harmonization is hard-fought and clever, blindsiding and mesmerizing upon first listen. Its mandated intricacy is what enraptures fans. Lifers don't merely tune in to Hiatus Kaiyote, they bask in it. That being said, Needle Paw, Palm's debut offering, can be seen as less of a proper solo outing and more of a grand fan service. It largely consists of minimal (or minimal compared to previous versions, more accurately) interpretations of existing HK songs as well as various covers.
The covers are thoughtfully handpicked. Palm doesn't wade in one genre for too long, and it's fun to see her palate of influences represented in one space. She borrows Bowie's beauteous stark message of being yourself and celebrating your inner weirdo. Ashanti gifts her with the inspiration and groove of rhythm-and-blues. Hendrix is responsible for both her flower child tendencies and at least five or so chords she and countless other likeminded guitarists have frequently copped since 1967. All of these progenitors are adapted seamlessly into her soulful rearrangements.
Needle Paw's most endearing aspect is its open mic feel. Featuring mostly Palm's guitar (fraught with as few overdubs as possible), her voice, and a small band of additional vocalists; the entire project's setup resembles that of a top-notch busking collective, and was accordingly recorded as such. Her guitar is the key ingredient – she plays an electric on clean setting for the majority of the time, but it's certainly not recorded through a direct input. Instead, it's mic'ed closely to the speaker on a low enough setting that the organic tactile moments (picking, popping of strings) still register on tape.
It's no surprise that the album's highlight blends her oeuvre with selections from her favorites, resulting in a written-out equation that solves for her current output. Using the root chord from "Breathing Underwater," but holding off on the song itself until the very end, she meanders expertly through a headstrong rendition of a section from the latter-day Bowie classic "Blackstar," then injects briefly but oh-so-ingeniously the refrain from Radiohead's "Pyramid Song," all before finally returning to home base to deliver an intoxicating choral-heavy iteration of her own past penmanship. Needle Paw fulfills any HK fan's dream of hearing an MTV Unplugged set from the foursome's mastermind, accompanied by an autobiographical music diary.
You may listen to the record at any of these outlets.
More in recordings
Deradoorian - Eternal Recurrence (anticon.)


Penélope Cruz, Oprah, Gisele Bündchen and more all use this tool for success.
Aniston's morning routine has a fixed meditation moment each day at 8:30 a.m. "There's usually some sort of meditation at that point. Usually 20 minutes, or 10 if I can't get the full amount of time in. It's a set [Transcendental Meditation mantra] that I do every time," she says.
You can make meditation a part of your mornings, too. It's refreshing to start the day by taking a few moments of stillness before you jump into checking your social media.
She says that meditation helps regain that stillness. "It's a sad and confusing predicament to be lost in the world — I know, because I've experienced time and again what that disconnectedness feels like. You start believing what the world has to say about you, whether it's the world in your head or the world outside. That outside world is constantly trying to convince you you're not enough. But you don't have to take the bait. Meditation, in whatever form you choose, helps you resist. What I know for sure, and have had to learn through much trial and error: The voice that truly matters is the silent voice of awareness, consciousness, aliveness," Winfrey says.
The supermodel and best-selling author told Arianna Huffington during the Thrive Global Podcast that meditation "gave me a new life" while battling extreme panic attacks during her early twenties. "Meditation gave me the opportunity to be aware of a new world I didn't know existed, and gave me the understanding that there was a place that no one could take away — that it was my own personal, sacred space that existed within myself, and all I needed to do was quiet my mind and go inward and connect to that," she says.
If 20 minutes feels like a tall order, and you're a meditation novice, know that it's also possible to feel energized with a moving meditation, like running in the park, or taking a yoga class.
Kerr shares her meditation experience with her son, Flynn. "When he sees me meditating, he'll come sit by me, just feeling the energy. He won't stay for the whole 10 or 20 minutes, but he'll join me for a bit," she says. "Every night before Flynn goes to bed, we'll also do a guided meditation that will put him to sleep. I have a few on my phone and he'll pick the one he wants. He'll just be like, 'I want this one!'" Everyone can benefit from meditation, no matter your age.
Kendall Jenner recently opened up to Allure about how after breaking through her initial skepticism about transcendental meditation and learning about it from a teacher, she began "to see such a difference in" the state of her mental health.
But while the model admits that she does "still have moments of panic attacks and anxiety," she describes the changes she's noticed since beginning this process: "I haven't had one (panic attack) in at least a year. Knock on wood and I have been pretty good and pretty steady. It's become such an important thing for me, and I definitely find myself in moments where I'm like, 'I need to sit down. 'Cause I'll go a couple of days or weeks without meditating, and I know that is wrong for me, I know I need to do it," she told the publication.
"Do meditative yoga for 10 minutes every morning. When you have a problem — whether it's road rage, your guy, or work — meditation allows everything to unfold the way it's supposed to," the actress told SHAPE in 2010. On top of the mental boost, yoga boasts health benefits, such as easing chronic pain.
Gisele Bündchen Swears by Her 20-Minute Daily Meditation Ritual. Here's Why.


text:
from Tkinter import *
from sys import *
import os
import platform
import lib
from lib import *

# Predefining Variables

# OOP Data

class CApplication():
    def __screen(self, event):
        w,h = event.width, event.height
        for config in self.configs:
            config(w,h)
    def __init__(self, width, height, title):
        # Predefining Variables
        self.configs = []

        self.root = Tk()

        # Root Bindings
        self.root.bind("<Configure>", self.__screen)

        # Base Values for different frameworks
        self.baseTitle = title
        self.baseWidth = width
        self.baseHeight = height

        self.root.title(title)

        self.root.geometry(str(self.baseWidth)+"x"+str(self.baseHeight)) # Setting the start window size
    def exe(self):
        self.root.mainloop()

class Menubar():
    def __init__(self, app):
        self.app = app
        self.menu = Menu(app.root)

    def Append(self, menu, lbl):
        self.menu.add_cascade(label=lbl, menu=menu)

    def retch(self):
        app.config(menu=self.menu)
        return app

class SubMenu():
    def __init__(self, menu):
        self.menu = menu
    def Append(self, item, options):
        if options["command"] != None and options["command"] != "":
            self.menu.add_command(label=item, command=options["command"])
        elif options["command"] == None or options["command"] == "":
            self.menu.add_command(label=item)

redpajama_set_name: RedPajamaGithub


text:
Wreck-it Ralph – New Poster Released from Walt Disney Studios
Wreck-It Ralph is in theaters November 2nd
Walt Disney Animation Studios and Emmy®-winning director Rich Moore
comes "Wreck-It Ralph," a hilarious, arcade-game-hopping adventure. For
decades, Ralph (voice of John C. Reilly) has been overshadowed by Fix-It
Felix, Jr. (voice of Jack McBrayer), the good-guy star of their game
who always gets to save the day. Tired of playing the role of a bad guy,
Ralph takes matters into his own massive hands and sets off on a
journey across the arcade through multiple generations of video games to
prove he's got what it takes to be a hero.
Enter the Play &
Win Sweepstakes! Complete missions, earn coins, and get the chance to
win a hero's journey from Adventures by Disney!
http://di.sn/k3h
You Can Help Legoland California Resort Break the World Record for the Most Vampires in One Place at One Time
Walt Disney Studios Has Released "Wreck-it Ralph" Trailer #2
Film & Movies1 day ago


text:
British Politicians' Addiction to Dueling
By Robert Meakin
Former Deputy Prime Minister John Prescott joined Labour candidates and activists ahead of the Scottish Labour Party Conference on March 26, 2010, in Edinburgh, Scotland.
SourceJeff J Mitchell/Getty Images
Because it beats fighting in a duel.
It was during a "clear the air" meeting between members of the U.K. Independence Party on October 6 this year that colleagues Steven Woolfe and Mike Hookem — both members of the European Parliament — bizarrely ended up settling their differences with a physical confrontation.
Woolfe, who was involved in a row over reports that he might leave UKIP and join the Conservative Party, told Hookem they should resolve their argument in an adjoining room. While the two men dispute what happened next, their "altercation" in Strasbourg concluded with Woolfe falling through an open door. What isn't in doubt is the fact that things got a whole lot worse after the dust-up. A couple of hours later, Woolfe collapsed and was hospitalized. He was discharged three days later, having suffered no serious injuries, but the confrontation proved a major embarrassment, and Woolfe quit the UKIP.
I am lucky to be alive … lucky that Mr. Adam's pistol was charged with government powder.
British politician Charles James Fox
But this duo weren't the first British politicians to abandon verbal debate for more hazardous hostilities. Some of the country's most powerful statesmen — including prime ministers — have even pulled a trigger on opponents in the past. One of the most controversial incidents took place in 1809 between senior government colleagues Lord Castlereagh and George Canning, when the former discovered the latter was plotting to get him fired. After agreeing to a duel with pistols one September morning, Canning was shot in the thigh. Despite coming away injured, he also suffered a bigger public backlash. Writing in his biography, Spencer Perceval: The Evangelical Prime Minister, author Denis Gray quotes Parliament member William Brodrick saying that Canning's conduct had "exceeded in duplicity everything that I ever felt possible, even in a politician."
The Duke of Wellington, meanwhile, is best remembered for his victory over Napoleon's France at the Battle of Waterloo in 1815. Much less celebrated is the duel he took part in while he was the country's prime minister 14 years later. The "Iron Duke" had reacted angrily to accusations of betrayal from the Earl of Winchilsea following the granting of new rights to Catholics. After challenging Winchilsea to a duel, they met at Battersea Fields, in south London, where Wellington is said to have deliberately missed with his first shot before the Earl chose to fire into the air. Honor was "satisfied," according to Neville Thompson's Wellington After Waterloo, when the prime minister received a written apology from his opponent. Others were unimpressed. "Wellington was torn apart," says James Landale, a BBC diplomatic correspondent and writer of the book Duel. "Political attitudes were changing … it was seen as absurd for a politician as senior as Wellington to behave in such a way." His career survived the incident with Winchilsea, but Wellington was forced to resign the following year, in 1830, over his opposition to parliamentary reform. He returned as foreign secretary — and then briefly again as prime minister — four years later, before finally retiring from political life in 1846.
While a gun duel involving another prime minister, William Pitt the Younger, in 1798 also ended with the two men (his opponent was George Tierney) missing each other, Pitt's famous political rival Charles James Fox had been shot in the chest 19 years earlier. After clashing with fellow politician William Adam over the quality of British gunpowder being used in the war with America, the two men met in London's Hyde Park in November 1779. Fortunate to be only slightly wounded, Fox couldn't resist making a cheeky political point: "I am lucky to be alive … lucky that Mr. Adam's pistol was charged with government powder."
The days of British politicians choosing to resolve their differences with dueling pistols are, of course, long gone. But that doesn't mean the odd fist doesn't occasionally fly. One punch landed Deputy Prime Minister Lord Prescott in big trouble in 2001. Struck by an egg when confronted by protesters during an election campaign visit to Wales, he reacted by hitting farm worker Craig Evans on the jaw. Colin Brown, author of the Prescott biography Fighting Talk, remembers how the incident divided opinion. "At that moment … the public either loved or hated him." Some colleagues figured Prescott's career was over, and many considered it outrageous that a "man holding historic office in government had been involved in fisticuffs," says Brown. But Prescott, a boxer in his youth, survived after it was successfully argued he'd acted in "self-defense."
Then again, Prescott's pugilism seems mild compared to the actions of Eric Joyce. The former Labour member of Parliament made headlines in 2012 after punching and head-butting Conservative politicians — as well as lashing out at one of his own party colleagues — when drunk in a House of Commons bar. Spared jail after pleading guilty to assault, Joyce, an ex-army officer, was again arrested the following year when clashing with police during a "disturbance" at a karaoke night. He finally left the Commons in 2015.
So whether it's left hooks or dueling pistols, grappling or headlocks, history seems to confirm that British politicians would always have been wiser to step back and count to 10 before putting their reputations — and sometimes even their lives — on the line. While fists and gunpowder have damaged and occasionally wrecked reputations, well-chosen words have proven the more effective political weapon.
Robert Meakin Contact Robert Meakin
The Next British Leader Must Salvage Both Brexit and Democracy
Chaos and indecision in London (and Washington) are giving "democracy" a bad name.
British Politicians Face More Threats Than Ever Before
Threats against members of Parliament are at "unprecedented" levels.
Parisian Street Gangs or Fashion Icons: Why Not Both?
In the early 20th century, the French capital's streets were ruled by this fabulous gang.
The Curse of Being the UK's Home Secretary
This cabinet position should be a powerful springboard to 10 Downing Street, but it has proven closer to being a poisoned chalice.
The 'Boy Wonder' Who Bounced Back
A political hit at age 16, Britain's William Hague discovered the cost of peaking too early.
Aaron Burr: From Founding Father to Founding Banker
One of the most famous personal conflicts in American history traces back to JPMorgan Chase's earliest predecessor bank.
The Ruthless Conquerer Who Cross-Dressed Her Way to Infamy
Catalina de Erauso wore her armor proudly — until she had to take it off to save her life.
The Plague of Being British Prime Minister
Many former U.
America's Little-Known Marco Polo
Lincoln appointed him the ambassador to China.
When a Paris Newspaper Pushed a Housewife to Murder
This French high-society lady closed out the Belle Époque with guns blazing — to defend her husband's honor.
The One Promise Politicians Should Be Making
Most folks get fired if they don't do their jobs.
Being a British 'Contender' Can Be a Curse
Peaking too early in the realm of politics comes at a price.
Wearables to Keep Politicians Honest
We should use tech to keep our politicians accountable to us.
The Gruesome History of Beheading
Beheading has a long tradition in the history of civilization.
Sajid Javid — Up and to the Right
A career adviser once told Sajid Javid that he should think about becoming a television repairman.


Commit to starting a project today and share it with the DayKnights.
Any topic is welcome: fitness, writing, education, programming and more.
Join discord.gg/day9tv. Desktop client is recommended.
Read our advice and create a project.
Say hi in the Discord channel matching your project category. Share your project and consider finding an accountabilibuddy.
Get started on your week 1 goals!
Set a calendar reminder to update your project with progress each week. Adjusting the scope is more common than not.
We'll periodically @ ping participants in Discord with words of encouragement.
Share your project with friends, family, and the DayKnight community!
Created with ♥ by Rezeyu.


Swimming lessons at St Mary's take place during the Summer Term. Lessons are offered to all pupils from Reception to Year 6 who wish to make use of this wonderful facility. The lessons consist of 10 weekly sessions and are provided by qualified swimming instructors where pupils will be taught in groups of 15 or less.


The in-office procedure typically does not need anesthesia and lasts about 5 minutes. This procedure is well-tolerated. Please click here to learn more about side-effects.
She makes a turn to our left down the street passing by a tree, and finally arriving at the Simpson house. The other news from the farm is first, The Weather. Lupron is also used widely off-label as a "down regulator" for women going through IVF treatment. Vote for it here.
Why not vasectomize males? Frightened, he looks behind his left shoulder, then behind his right, and then opens the door leading into the downstairs hallway of the house In " Bart the Genius ", Homer's scream is absent. Many of the symptoms treated by the MonaLisa Touch are associated with low hormone levels brought on by menopause.
That was my first introduction, a long, long time ago, to the fact that not all health care professionals believe that spaying and neutering young dogs is in their best interest. One recent study, on Golden Retrievers by Torres de la Riva et al at UC-Davisfound that males neutered before the age of 12 months were twice as likely to suffer from hip dysplasia, and that three times more early-neutered males suffered from lymphosarcoma than intact males.
On the other hand, late-neutered after 12 months females suffered from hemangiosarcoma four times more than intact or early-neutered females. However, another study just came out by Hoffman, Creevy and Promislowthat found a correlation between reproductive sterilization and a longer life span when neutered dogs were compared to intact dogs.
In part, that increased longevity was associated with a decreased risk of death from infectious diseases and trauma. However, they also found that neutering was correlated with an increased risk of death from cancer.
Whatever are we to make of these findings? Should American pet owners forgo neutering their pet dogs in order to increase their life span or prevent joint and tissue injuries?
More murders are found in cities with a lot of traffic lights. For example, the study by Hoffman, Creevy and Promislow found that neutered dogs lived longer than intact ones, but how do we know that being neutered was what caused the dogs to live longer?
Perhaps neutered animals represent a different demographic, with different health care histories, different diets, different levels of health care, etc.
Natural selection is a conservative process, and it is rare for any hormone to play only one role in the body.
Androgens produced in the testes play a role in muscle and skeletal development. Lupron is used for a variety of purposes. It is prescribed to children to treat early-onset puberty, to men who exhibit symptoms of prostate cancer in men, and to women with endometriosis, a condition in which the uterine lining grows outside the uterus.
Lupron is also used widely off-label as a "down regulator" for women going through IVF treatment. Patients take Lupron in a single day dose in the form of daily shots. Lupron Depot is given in an extended release injection that lasts for 30 days.
At least one expert believes Lupron should be pulled from the market.
Lupron temporarily stops menstruation, but does not eradicate endometriosis for long-term. I have also increased my fruit and vegetable intake. Try to change your diet and see if your acne reduces.
NEVER had it as a teen. SO it has been hell for me!! I was ready to give up, but i'm not one to quit. SO hope these help you.
Stevia rebaudiana leaves by A. I've tride every thing in stores and it all makes it worse: Upon entering their house, they run towards the living room couch, with a different gag occurring with the exception of "Bart the General" and "Life on the Fast Lane".
I would also advice you to stay away from any type of wipes, they have too much chemicals in them, which irritates ur skin and causes u to break out! All this has done wonders for me and ive gone for months without a spot.
But remember its a combination of thing, your diet, stay away from acidic food. Sun is good for ur skin ofcourse with spf protection.
And the best thing externally is Aloe Vera, invest and buy the plant! Do this for 2weeks inlcuding a good diet, staying away from harsh chemicals e. Dose any body know any products that an get rid of my acne with out makeing it worse?
I had a consultation yesterday with the doctor to schedule the Mona Lisa touch After five years of urinary trac infections as a result of the atrophy I'm going to go for it.
I've tride every thing in stores and it all makes it worse: I don't know what to do!!! Aloe Vara should be taken by mouth and applyed on the face, If you take it by mouth it should help clear from the inside to the out.
Peel and mash eight cloves of fresh garlic and apply to face avoiding the area around the eyes. Leave on for about 15 minutes and wash off with a warm cloth. I looked at ur comments n suggestions and wus wonderin' whether ammmmm. But I myself m concious abt itm I will continue to use it for 2 weeks and if it doesn't get better i am stuck so does proactiv really work?????
My acne is extremely bad,big,nasty. Also use spot treatment at night and apply directly to the pimple after using the heat. I have scaring from my previouse pimples on my forehead and on my chin. I use proactive which has made a difference but not too much of a difference.
I NEED to get rid of it because its annoying and ugly and it really brings down your self confidence. I just want to hide my face from the world.
This really works, get a juicer and juice whole carrots.
Use the foamy stuff on top of the juice and put it all over your face. Wash off gently with water only. At night before bed use small amount tea tree oil face wash. Natures gate acne spot corrector. Use vit E and put on skin at night if it feels to dry.


PIZZA TIME with Cauliflower Crust!!!
I browsed several recipes and played around with the balance of ingredients. I was amazed how well this work, and that the crusts really stuck together! I even froze some of them, and pull them out when desired!
Toss everything in a bowl and mix it up! I brushed each with a little olive oil. I formed small pizza crusts and baked them them at 375 degrees for about 10 minutes. Just watch them. When they are browned, take them out and let them cool.
Using the crusts – let your creativity come out! I used some chicken, mozza, small tomatoes, and tomato sauce for one creation. For another, I used some sautéed spinach, small tomatoes, and feta for another. Whatever your heart desires – go for it!!!
Keep it simple. Eat real food, eat fresh food. Game is a great way to enjoy read meat as it is leaner, and easier to digest. Whatever root vegetables are in season will work here. Anytime of greens will work as well. Try out your local farmer's market, and pick some things you haven't had before.
To roast the squash, simply slice into reasonable sized pieces. The buttercup squash isn't too big, so I cut it into eights. Rub in olive oil, sprinkle with sea salt, and bake at 400 degrees until browned and soft (probably 30 to 45 minutes depending on size).
To soften the kale, massage in olive oil and let rest. Add ripe, sliced tomatoes when ready to serve.
The meat. Rub in olive oil, sprinkle with sea salt. When the squash is roasted, let it rest while you cook the meat. Heat pan on medium high for a few minutes – to ensure it is nice and warm. Add a little olive oil. Sautee the meat for 2 to 3 minutes on each side, until nice and brown. Then turn the heat down and continue to cook, turning often, until desired cook is reached. Medium rare is really nice…a bit pink inside, but warmed through. Let it rest for a couple of minutes after you take it off the heat, and slice.
Keep it simple. Good ingredients will fuel you for all those activities you love!!
Summer is a great time for meal sized salads!!! This one is SO good. Candy beets are quite sweet, raw or cooked. And the color just adds some summer fun to your plate!
Peel the candy beets, then slice into small chunks. Toss them in olive oil. Place this in a tin foil 'package', salt, then place on hot grill for 30-45 minutes. Take them off when they are soft to pierce with a force, and nicely browned.
Gently rub olive oil over the chicken breasts. Grill them on medium-high heat for about 5 minutes on each side. Make sure they are cooked through.
Mix together 1 tablespoon of olive oil and 1 teaspoon of a rose vinegar (or vinegar of your choice). I like the rose because it is sweet and compliments the beets. Pour over the greens and toss.
Slice the chicken breasts, and present on the plate however you wish. I like to place the beets and greens together and the chicken breast on the side.


text:
Home > news, Race Car Events, supra > SATS Cosworth Supra BDC Round 3
SATS Cosworth Supra BDC Round 3
July 7th, 2011 Administrator
Horseless Carriage Sliding – SATS Cosworth at round 3 of the British Drift Championship from Ciaran Smith on Vimeo.
Team SATS Cosworth were at Teesside Autodrome on the weekend of 2/3 July for round 3 of the Maxxis Tyres British Drift Championship
Having suffered some engine issues at the previous round, the team worked hard over the course of the past few weeks to have the car ready for the event. Team Mechanic Simon Edwards told us,
"The engine was taken back out, checked, and we found a couple of things wrong. It was nothing major, just stuff that needed to be addressed. So while we were there, we took the time to rebuild and refresh it, and made sure that it was built to the same tolerances as the last engine."
So with the car ready to go, Mark went out on his qualifying runs, and pulled off some awesome displays, staying within inches of the clipping points. However, he was marked down heavily for using the handbrake too much on the straight; something he didn't know would be an issue until speaking to the judges afterwards. He qualified in 9th place.
The team put the result behind them, and got the car ready for competition the following day. His first opponent was to be Simon Perry in his Nissan Skyline.
In the first run, Mark was chasing, with Perry leading. Both drivers almost had their cars backwards exiting the first corner such was the angles they were pulling. At one point, Mark straightened slightly, as he had to brake to avoid a collision with Perry. However, this was the least of his worries.
With so much smoke emanating from Perry's tyres, Mark lost sight of the track and clipped the tyre wall with the rear of the car, ripping off the bumper in the process. As a result, Perry scored 10-0.
Knowing that his chances at progressing to the next stage of the competition were slim, Mark went out anyway on his leading run, and put on a show for the crowds, driving possibly one of the best runs of the day, leaving his opponent Perry in the distance.
Afterwards, Mark told us,
"Qualifying wasn't as we expected. 9th place just wasn't what we were looking for. It seemed that even though we had fast, consistent runs, it wasn't the lines that the judges wanted."
On his drive against Perry, he said,
"We knew we had the worst draw in the top 16, up against Simon Perry. We went out and gave it everything we had on the first run, but just got it slightly wrong on the last corner, ran wide, and caught the tyre wall. It's caused quite substantial damage to the back of the car. Even though we beat Simon on the second run, it wasn't enough to beat his 10-0".
With the work performed on the engine since the last round, Mark was full of praise for the car,
"Mechanically, the car was fantastic. The new Cosworth engine fitted to it ran really good. The car was brilliant all weekend, but it just wasn't to be."
So a disappointing result for the team, but you can be sure they will be back, and raring to go, and one of Mark's old stomping grounds, Knockhill.
-Release and Media prepared by SATS Cosworth
Categories: news, Race Car Events, supra Tags: British Drift Championship, Cosworth, Drift Supra, Maxxis, SATS, Teesside Autodrome, titan motorsports
Ny-Trex Purges Your Nitrous, Not Your Wallet. MSD's Rev'n in '11!!


Lyme disease is a bacterial infection spread to humans by infected ticks. Ticks are tiny spider-like creatures found in woodland and heath areas.
They feed on the blood of birds and mammals, including humans. Ticks that carry the bacteria responsible for Lyme disease are found throughout the UK.
We take all risks at the places we care for seriously, including Lyme disease. Each of our places assesses the risks which are present. The staff members at our places develop bespoke approaches to managing those risks for staff, volunteers and visitors.
Our staff members have access to internal information on Lyme disease which includes guidance from NHS Choices and Public Health England on the prevention and diagnosis of Lyme disease and tick removal. Information and guidance for visitors about Lyme disease is available at the places we care for, where we've identified a material risk.
For more information on Lyme Disease, visit NHS Choices and Public Health England websites.
We'd always encourage anyone who has been bitten by a tick after visiting one of our places and/or had a diagnosis of Lyme disease to contact the place they visited directly. This will enable us to look into the situation further. Since 2010 we have received four reports of Lyme disease or tick bites, two of which were from visitors.
Many of our places are as mad about dogs as you are. Find out more about bringing your dog with you.
We've hundreds of walks just waiting to be discovered at our amazing places. Where will you go?


At ↑Tom Hall's weblog I ↑read that Bethesda has celebrated the 20th birthday of 'Wolfenstein 3D' (id Software 1992) by putting it online as a free browser game. But when I clicked ↑the link I got a 404—it ain't here anymore. Either Bethesda has taken it offline again, or the fabulous German banning mechanisms kicked in. I am too lazy to go via proxy, especially because there's another solution. At Virtual Apple you can ↑play that milestone of computer game history via an Apple ][ emulation.
ID SOFTWARE. 1992. Wolfenstein 3-D [computer game]. Mesquite et al.: id Software et al.
Yes what have you toughten? If se government allows Wolfenstein, there could everybody coming!
rofl. You, Sir, are absolutely right, of course. Btw, they ↑revoked the ban on 'Doom' … in August 2011.


Delta World Tire Company provides Struts Replacement services to South Louisiana, the Mississippi Gulf Coast, the Gulf Coast Region, and other surrounding areas.
Why Should You Have Struts Replacement Services Performed at Delta World Tire Company?
We proudly service the Struts Replacement needs of customers in South Louisiana, the Mississippi Gulf Coast, the Gulf Coast Region, and surrounding areas.